For the year ending 2025-12-31, EVMN had $29,015K increase in cash & cash equivalents over the period. -$76,676K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -68,870 |
| Stock-based compensation expense | 5,856 |
| Accretion of discount on investments | 1,769 |
| Depreciation and amortization | 1,389 |
| Change in fair value of convertible preferred stock forward | 8,928 |
| Prepaid expenses and other assets | 2,370 |
| Accounts payable | -837 |
| Accrued liabilities | 2,818 |
| Operating lease liabilities | -730 |
| Deferred revenue | -3,000 |
| Net cash used in operating activities | -76,441 |
| Purchases of investments | 199,172 |
| Maturities of investments | 84,100 |
| Purchase of property and equipment | 235 |
| Net cash used in investing activities | -115,307 |
| Proceeds from the sale of common stock in initial public offering, net of offering costs paid | 157,284 |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | 65,228 |
| Proceeds from exercise of stock options | 6 |
| Principal payments of finance lease liability | 373 |
| Principal payments of financing obligation | 158 |
| Taxes paid related to net share settlement of equity awards | 1,224 |
| Net cash provided by financing activities | 220,763 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 29,015 |
| Cash, cash equivalents and restricted cash - beginning of year | 16,463 |
| Cash, cash equivalents and restricted cash - end of year | 45,478 |
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)